X. Fang

发表

High-efficiency gene transfer and high-level expression of wild-type p53 in human lung cancer cells mediated by recombinant adenovirus.

J. Roth, B. A. French, W. Zhang, 1994, Cancer gene therapy.

CircDIDO1 inhibits gastric cancer progression by encoding a novel DIDO1-529aa protein and regulating PRDX2 protein stability

Yu Zhang, H. Cai, H. Qian, 2021, Molecular cancer.

Comparative efficacy and safety of PD-1/PD-L1 Inhibitors versus platinum-based chemotherapy for the first-line treatment of advanced non-small cell lung cancer: a meta analysis of randomized controlled trials.

X. Fang, Ming-Kui Zhang, Jingjing Gu, 2020, Pharmacological research.

A correlation study of the expression of HA-CD44st and HER-2 in breast cancer

Zhang Xu, L. Ning, X. Fang, 2018, OncoTargets and therapy.

ras transformation of simian virus 40-immortalized rat hepatocytes: an in vitro model of hepatocarcinogenesis.

R. Cameron, A. Keating, M. Sherman, 1992, Cancer research.

Doxorubicin induces drug resistance and expression of the novel CD44st via NF-κB in human breast cancer MCF-7 cells.

Ye Tian, Yaqun Zhu, Hua Jiang, 2014, Oncology reports.

Polymorphisms in thymidylate synthase and reduced folate carrier (SLC19A1) genes predict survival outcome in advanced non-small cell lung cancer patients treated with pemetrexed-based chemotherapy

H. Ye, Hua Jiang, X. Fang, 2013, Oncology letters.

rahydrofolate reductase (MTHFR) and reduced folate carrier (SLC19A1) gene polymorphisms and the treatment efficacy of pemetrexed-based chemotherapy in advanced non-small cell lung cancer (NSCLC). Advanced NSCLC patients received pemetrexed and cisplatin every three weeks. Polymorphisms in the TS, MT

Hua Jiang, X. Fang, Chunluan Yuan, 2013 .

AC0010, an Irreversible EGFR Inhibitor Selectively Targeting Mutated EGFR and Overcoming T790M-Induced Resistance in Animal Models and Lung Cancer Patients

Xiaoying Zhang, Xiao Xu, Ji Jiang, 2016, Molecular Cancer Therapeutics.

Efficacy and Safety of Programmed Cell Death 1 Inhibitor Monotherapy Versus Chemotherapy as Second-Line Treatment for Advanced Esophageal Cancer: A Meta-analysis and Systematic Review.

X. Fang, Guanhong Huang, Jingjing Gu, 2021, Clinical therapeutics.

MA16.06 Phase I/II Study of AC0010, Mutant-Selective EGFR Inhibitor, in Non-Small Cell Lung Cancer (NSCLC) Patients with EGFR T790M Mutation

Ying Cheng, Yi-long Wu, Li Zhang, 2017 .

The v-raf oncogene enhances tumorigenicity and suppresses differentiation in vivo in a rat hepatocyte cell line.

G. Mills, A. Keating, M. Sherman, 1993, Carcinogenesis.

The role of a new CD44st in increasing the invasion capability of the human breast cancer cell line MCF-7

Hua Jiang, X. Fang, Wei Jiang, 2011, BMC Cancer.

Effect of CD44st and HER2 expression on the postoperative prognosis of breast cancer patients

Dan Chen, X. Fang, Guanjun Huang, 2019, OncoTargets and therapy.

Expression of Novel CD44st and MMP2 in NSCLC Tissues and Their Clinical Significance

Ning Li, Lei Zhang, Hua Jiang, 2017, Oncology Research and Treatment.

[VEGF shRNA enhances the sensitivity of multidrug-resistant leukemia cells to anticancer agent].

Li-li Fang, Juan Li, Wenlin Xu, 2011, Zhongguo shi yan xue ye xue za zhi.